<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051241</url>
  </required_header>
  <id_info>
    <org_study_id>GFH018X1101</org_study_id>
    <nct_id>NCT05051241</nct_id>
  </id_info>
  <brief_title>A Study of GFH018 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study With Single/Multiple Dose Administered to Explore the Safety/Tolerability and Pharmacokinetics of GFH018 in the Treatment of Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Genfleet Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfleet Therapeutics (Shanghai) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first in human study of GFH018 comprised of a dose escalation part and a dose&#xD;
      expansion part in subjects with advanced solid tumors after single/multiple administration.&#xD;
      The study is designed to explore the safety/tolerability, pharmacokinetics, and MTD of GFH018&#xD;
      and to define a RP2D of GFH018.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Iï¼šIncidence of dose-limiting toxicity (DLT) events</measure>
    <time_frame>31 days after the first dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>GFH018</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The duration of the first cycle is 31 days and the subsequent periods are 28 days.&#xD;
Subjects will receive treatment with GFH018 until disease progression (clinically- or radiologically-confirmed), occurrence of intolerable toxicity, or subjects discontinue from the study treatment for other reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFH018</intervention_name>
    <description>Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen.</description>
    <arm_group_label>GFH018</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible subjects must meet all the inclusion criteria listed below:&#xD;
&#xD;
               1. Voluntarily participate in this clinical trial, and are willing to sign informed&#xD;
                  consent forms.&#xD;
&#xD;
               2. Male or female aged from 18-75 years old (inclusive).&#xD;
&#xD;
               3. Diagnosed with histologically or cytologically confirmed advanced solid tumors.&#xD;
&#xD;
               4. Evaluable lesions defined by RECIST v1.1.&#xD;
&#xD;
               5. Eastern Cooperative Oncology Group performance status of 0 to 1.&#xD;
&#xD;
               6. Subjects or their legal representatives are able to communicate well with&#xD;
                  Investigators and are willing to comply with the protocol and complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible subjects should not meet any of the exclusion criteria listed below:&#xD;
&#xD;
               1. With clinically significant cardiac diseases.&#xD;
&#xD;
               2. With clinically significant digestive disorders.&#xD;
&#xD;
               3. Other severe disease.&#xD;
&#xD;
               4. Pregnant or lactating women.&#xD;
&#xD;
               5. Other unfavorable situations for subjects to participate in the study judged by&#xD;
                  Investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leading site</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Liu</last_name>
    <phone>+86 21 6882 1388</phone>
    <email>wliu@genfleet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jin Li, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

